Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 15.59 | 12.67 | — | 5.72 | 7.81 | 7.15 | 12.42 | 1.96 | 1.55 | — | — | 4.16 | 5.48 | 19.61 | 26.01 | — | — | 3.39 | — | 7.60 | — |
| — | +77.3% | — | +192.6% | +402.2% | — | — | -53.0% | -71.6% | — | — | — | — | +478.0% | — | — | — | — | — | — | — | |
| P/S Ratio | 2.12 | 1.89 | 1.81 | 1.02 | 1.24 | 0.82 | 0.80 | 0.64 | 0.39 | 0.84 | 1.46 | 0.72 | 0.56 | 0.76 | 0.69 | 0.74 | 0.47 | 0.54 | 0.66 | 0.56 | 1.55 |
| — | +130.2% | +125.8% | +59.3% | +218.9% | -1.9% | -45.0% | -11.5% | -30.5% | +9.5% | +111.4% | -2.3% | +18.5% | +40.6% | +3.9% | +30.9% | -69.4% | -68.8% | -34.4% | -71.0% | -21.6% | |
| P/B Ratio | 3.70 | 3.08 | 2.53 | 2.35 | 2.35 | 1.64 | 1.52 | 1.64 | 1.76 | 3.25 | 5.01 | 3.89 | 3.25 | 5.48 | 5.64 | 8.97 | 4.87 | 6.55 | 17.01 | — | — |
| — | +87.5% | +66.3% | +43.8% | +33.0% | -49.4% | -69.6% | -58.0% | -45.7% | -40.8% | -11.1% | -56.6% | -33.4% | -16.3% | -66.9% | — | — | -48.1% | -29.6% | — | — | |
| P/FCF | 11.60 | 65.66 | 5.27 | 5.30 | 7.00 | 3.06 | 10.40 | 2.42 | 2.85 | 39.08 | 5.68 | 5.00 | 2.97 | 12.90 | — | 70.93 | 1.56 | — | — | — | 6.81 |
| — | +2047.4% | -49.3% | +119.4% | +145.9% | -92.2% | +83.2% | -51.6% | -4.2% | +202.9% | — | -93.0% | +89.8% | — | — | — | -77.0% | — | — | — | -88.4% | |
| EV / EBITDA | 10.01 | 7.78 | — | 3.86 | 5.25 | 4.43 | 5.40 | 2.40 | 1.45 | 64.77 | 120.98 | 3.32 | 3.41 | 7.07 | 6.83 | 4.74 | 7.45 | 3.31 | 25.40 | — | — |
| — | +75.6% | — | +61.0% | +262.4% | -93.2% | -95.5% | -27.7% | -57.5% | +816.7% | +1670.6% | -30.0% | -54.3% | +113.7% | -73.1% | — | — | — | +454.8% | — | — | |
| EV / EBIT | 12.95 | 11.72 | — | 4.19 | 6.01 | 5.20 | 6.72 | 2.62 | 1.52 | — | — | 3.81 | 4.55 | 9.74 | 10.18 | — | 13.65 | 3.96 | — | 6.23 | — |
| — | +125.1% | — | +60.1% | +294.4% | — | — | -31.3% | -66.5% | — | — | — | -66.7% | +146.0% | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 74.5% | 77.9% | 76.7% | 69.3% | 77.7% | 76.5% | 77.1% | 76.4% | 63.9% | 77.4% | 75.5% | 66.3% | 76.3% | 78.3% | 75.0% | 74.4% | 78.1% | 74.9% | 76.3% | 78.5% | 77.8% |
| — | +1.8% | -0.4% | -9.3% | +21.6% | -1.1% | +2.1% | +15.3% | -16.3% | -1.2% | +0.7% | -10.8% | -2.3% | +4.5% | -1.8% | -5.3% | +0.4% | -3.4% | +9.2% | -0.8% | -3.3% | |
| Operating Margin | 16.3% | 13.4% | -8.5% | 22.7% | 17.6% | 12.7% | 8.7% | 22.6% | 27.4% | -4.6% | -5.3% | 20.5% | 15.3% | 9.0% | 8.3% | 15.3% | 4.2% | 20.3% | -1.6% | -42.6% | -19.4% |
| — | +6.1% | -198.6% | +0.2% | -35.9% | +373.5% | +264.9% | +10.3% | +79.2% | -151.6% | -163.5% | +34.4% | +265.1% | -55.7% | +606.4% | +135.8% | +121.6% | +165.0% | -108.0% | -100.8% | +19.0% | |
| Net Margin | 13.6% | 14.5% | -8.4% | 17.8% | 16.2% | 11.2% | 6.5% | 32.7% | 25.2% | -9.6% | -11.0% | 17.0% | 10.3% | 3.9% | 2.7% | -8.5% | -0.6% | 15.7% | -7.4% | 7.6% | -96.6% |
| — | +29.8% | -229.6% | -45.5% | -35.6% | +216.1% | +158.8% | +92.3% | +144.2% | -346.9% | -514.4% | +299.1% | +1738.2% | -75.3% | +135.7% | -211.9% | +99.3% | +264.6% | -144.2% | +126.7% | -55.8% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 28.0% | 6.1% | -2.9% | 10.9% | 8.0% | 5.8% | 3.1% | 23.7% | 34.0% | -9.1% | -9.2% | 26.6% | 16.8% | 7.6% | 5.9% | -25.6% | -1.7% | 69.7% | -144.8% | — | -481.7% |
| — | +5.7% | -192.3% | -53.7% | -76.3% | +163.7% | +134.1% | -11.1% | +102.7% | -220.4% | -256.2% | +203.9% | +1075.5% | -89.2% | +104.1% | — | +99.6% | +413.4% | -145.9% | — | -75.7% | |
| ROA | 14.5% | 4.2% | -1.8% | 6.4% | 4.4% | 3.0% | 1.5% | 8.9% | 9.5% | -2.2% | -2.2% | 5.7% | 2.9% | 1.1% | 0.7% | -2.7% | -0.2% | 4.8% | -1.6% | 1.9% | -18.4% |
| — | +41.9% | -226.3% | -27.9% | -53.4% | +238.6% | +167.1% | +57.4% | +232.7% | -301.6% | -423.3% | +312.1% | +1663.3% | -77.5% | +142.0% | -242.8% | +99.0% | +341.4% | -124.2% | +131.5% | -53.4% | |
| ROIC | 24.7% | 5.3% | -2.4% | 11.1% | 7.1% | 5.1% | 3.1% | 10.7% | 19.5% | -2.0% | -2.1% | 14.8% | 8.4% | 4.5% | 4.8% | 12.6% | 2.5% | 12.8% | -1.0% | -37.9% | -13.0% |
| — | +3.7% | -178.0% | +3.2% | -63.5% | +357.4% | +248.6% | -27.9% | +130.5% | -143.6% | -143.9% | +17.4% | +233.1% | -64.4% | +568.2% | +133.4% | +119.5% | +152.6% | -102.4% | -35.8% | +40.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.22 | 0.03 | 0.12 | 0.22 | 0.36 | 0.47 | 0.64 | 0.80 | 1.21 | 2.03 | 2.17 | 2.09 | 2.90 | 3.72 | 4.40 | 5.29 | 5.19 | 5.85 | 16.25 | — | — |
| — | -92.6% | -80.5% | -72.8% | -70.7% | -76.9% | -70.7% | -61.5% | -58.1% | -45.3% | -50.6% | -60.6% | -44.1% | -36.5% | -72.9% | — | — | +42.2% | +120.5% | — | — | |
| Debt / EBITDA | 0.59 | 0.38 | — | 1.44 | 3.34 | 5.24 | 9.10 | 4.57 | 3.46 | 135.24 | 185.18 | 6.30 | 9.79 | 14.54 | 15.69 | 9.35 | 23.63 | 7.96 | 67.89 | — | — |
| — | -92.7% | — | -68.4% | -3.5% | -96.1% | -95.1% | -27.5% | -64.7% | +830.2% | +1080.3% | -32.6% | -58.6% | +82.8% | -76.9% | — | — | — | +1194.5% | — | — | |
| Current Ratio | 2.00 | 2.91 | 2.38 | 2.00 | 1.74 | 1.73 | 1.53 | 1.54 | 1.42 | 1.32 | 1.46 | 1.57 | 1.86 | 1.97 | 2.32 | 1.73 | 2.04 | 2.01 | 1.57 | 1.28 | 1.18 |
| — | +68.6% | +55.7% | +30.3% | +22.2% | +30.8% | +5.0% | -2.2% | -23.7% | -32.9% | -37.2% | -9.3% | -8.8% | -2.2% | +47.5% | +35.6% | +73.2% | +65.3% | +34.8% | -0.1% | -12.9% | |
| Quick Ratio | 1.93 | 2.64 | 2.24 | 1.93 | 1.62 | 1.62 | 1.43 | 1.45 | 1.40 | 1.23 | 1.38 | 1.50 | 1.78 | 1.84 | 2.24 | 1.67 | 1.95 | 1.89 | 1.47 | 1.21 | 1.12 |
| — | +63.4% | +56.6% | +33.8% | +16.1% | +31.2% | +3.2% | -3.7% | -21.4% | -32.9% | -38.2% | -10.4% | -8.8% | -2.8% | +51.8% | +38.1% | +74.7% | +63.1% | +32.7% | -2.9% | -15.8% | |
| Interest Coverage | 6.40 | 46.81 | -3.69 | 16.29 | 7.21 | 4.36 | 2.50 | 5.67 | 7.65 | -0.23 | -0.37 | 4.60 | 2.57 | 1.70 | 1.47 | -0.62 | 0.90 | 4.49 | -0.26 | 2.63 | -13.30 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PBYI stock.
Puma Biotechnology, Inc.'s current P/E is 15.6x. The average P/E over the last 3 quarters is 8.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Puma Biotechnology, Inc.'s current operating margin is 16.3%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Puma Biotechnology, Inc.'s business trajectory between earnings reports.